- Zacks•7 days ago
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Accesswire•11 days ago
NEW YORK, NY / ACCESSWIRE / March 16, 2017 / One question many investors have is how much emphasis should be put on insider trading reports and institutional investor activity. The recent activity of TG ...
- Business Wire•15 days ago
ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that data from a mirvetuximab soravtansine Phase 1 biopsy expansion cohort demonstrate that archival tumor tissue can reliably identify patients with folate receptor alpha -positive platinum-resistant ovarian cancer.
IMGN : Summary for ImmunoGen, Inc. - Yahoo Finance
ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||3.67 x 1600|
|Ask||3.68 x 2300|
|Day's Range||3.54 - 3.74|
|52 Week Range||1.51 - 9.78|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.02|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|